Transaction with Wuhan Dahong Enterprise Management Partnership (LP), or Wuhan Dahong.Wuhan Dahong holds non-controlling equity interest in Wuhan Yunteng Logistics Co., Ltd., one of our principal subsidiaries. As of December 31, 2016, 2017 and 2018, we had nil, nil and RMB14,000 (US$2,036), respectively, due from Wuhan Dahong, representing the payment made on behalf of Wuhan Dahong for its incorporation fees. The outstanding balance has been fully repaid and there is no amount due from the related party as of the date of this prospectus.
Transaction withLanlan Ltd. Lanlan Ltd. is one of our principal shareholders and wholly-owned by Mr. Shanglue Xiao, our chairman and chief executive officer. As of December 31, 2016, 2017 and 2018, we had nil, nil and RMB8,000 (US$1,163), respectively, due from Lanlan, representing the payment made on behalf of Lanlan for its incorporation fees. The outstanding balance has been fully repaid and there is no amount due from the related party as of the date of this prospectus.
Transactions with Our Equity Investees
Transaction withHangzhou Tianshi Technology Co. Ltd., or Tianshi.Tianshi is our equity investee and our supplier. As of December 31, 2016, 2017 and 2018, we had nil, nil and RMB5.6 million (US$0.8 million), respectively, due to Tianshi, representing the payments due to Tianshi for products purchased from Tianshi.
Transaction withHangzhou Zhangtaihe Health Technology Co., Ltd, or Zhangtaihe.Zhangtaihe is our equity investee and our supplier. As of December 31, 2016, 2017 and 2018, we had nil, nil and RMB5.0 million (US$0.7 million), respectively, due to Zhangtaihe, representing the payments due to Zhangtaihe for products purchased from Zhangtaihe.
Transaction withGuangdong Weixin Technology Co Ltd., or Guangdong Weixin.Guangdong Weixin is our equity investee and our supplier. As of December 31, 2016, 2017 and 2018, we had nil, nil and RMB70,000 (US$10,181), respectively, due to Guangdong Weixin, representing the payments due to Guangdong Weixin for products purchased from Guangdong Weixin.
Transaction withBeijing Siwei Technology and Culture Co., Ltd., or Beijing Siwei.Beijing Siwei is our equity investee and our supplier. As of December 31, 2016, 2017 and 2018, we had nil, nil and RMB0.2 million (US$27.2 thousand), respectively, due to Beijing Siwei, representing the payments due to Beijing Siwei for products purchased from Beijing Siwei.
Transaction withHangzhou Adopt A CowBiological Technology Co., Ltd., or Hangzhou Biological Technology.Hangzhou Biological Technology is our equity investee and our supplier. As of December 31, 2016, 2017 and 2018, we had nil, nil and RMB0.6 million (US$0.1 million), respectively, due to Hangzhou Biological Technology, representing the payments due to Hangzhou Biological Technology for products purchased from Hangzhou Biological Technology.
We believe the terms of the transactions with Tianshi, Zhangtaihe, Guangdong Weixin, Beijing Siwei and Hangzhou Biological Technology are comparable to those with third-party suppliers.
Participation in Offering
Our existing shareholders, Crescent Point and Trustbridge Partners, have indicated an interest that they or their affiliates may purchase an aggregate of up to US$100 million worth of the ADSs being offered in this offering at the initial public offering price. Assuming an initial public offering price of US$12.00 per ADS, which is the mid-point of the estimated offering price range, the number of ADSs to be purchased by these existing shareholders or their affiliates would be up to 8,333,334 ADSs. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell more, fewer or no ADSs to any of these potential purchasers, and any of these potential purchasers could determine to purchase more, fewer or no ADSs in this offering.
163